The Food and Drug Administration (FDA) has cleared the Propeller Health digital platform to connect with the Symbicort® Inhaler (budesonide, formoterol fumarate dihydrate; AstraZeneca), a corticosteroid and long-acting beta-2 agonist indicated for the treatment of asthma and COPD. The Propeller platform includes a sensor that is attached to the inhaler. The sensor delivers insights on…
The first-in-class tyrosine kinase inhibitor masitinib decreased asthma exacerbations greater than placebo in patients with severe asthma uncontrolled by oral corticosteroids.
In patients with COPD, treatment with single-inhaler fluticasone furoate/umeclidinium/vilanterol resulted in more health status improvements and greater lung function benefit compared with multiple-inhaler triple therapy.
Patients with severe eosinophilic asthma who are treated with mepolizumab and subsequently stop treatment have increased blood eosinophil counts and increased exacerbations, among other negative clinical outcomes.
Patients with severe eosinophilic asthma who are treated with mepolizumab and subsequently stop treatment have increased blood eosinophil counts and increased exacerbations, among other negative clinical outcomes.
Patients with asthma-chronic obstructive pulmonary disease overlap may have an increased independent risk for lung cancer that is similar to those with COPD, but higher than smokers with asthma and normal spirometry values.
CSJ117, formulated as an engineered powder in hard capsules for delivery to the lungs via dry powder inhaler, may be the first inhaled anti-thymic stromal lymphopoietin treatment for adults with mild asthma.
The product is indicated for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.
Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol provided greater increases in lung function compared to once-daily fluticasone furoate/vilanterol in patients with poorly controlled asthma.
FEV1 increased in patients with aspirin-tolerant asthma while on standard asthma treatment but declined in patients with aspirin-exacerbated respiratory disease.
